BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.94 --0%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
SYRS, EGRX, AIFC, More
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
SYRS, EGRX, AIFC, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
- Citi sees strong hardware OEM results driven by AI demand
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
